TSHA — Taysha Gene Therapies, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1806310 ·
Last close
$4.00
Market Cap
$1.30B
52W High
$7.30
52W Low
$3.45
ADV30
3,661,562
Next earnings
2026-11-12
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -50,782,000 -46,639,000 470,433,000 455,407,000 83,167,000
Mar 2026 0 — -43,486,000 -42,410,000 300,351,000 276,576,000 88,407,000
Dec 2025 5,485,000 — -28,300,000 -27,851,000 343,320,000 319,767,000 96,382,000
Sep 2025 0 — -34,024,000 -32,733,000 316,554,000 297,344,000 97,565,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-132,191,000
Investing CF
$-3,318,000
Financing CF
$275,719,000
CapEx
$-3,384,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-800,349,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-149,591,000
Pretax Income TTM
$-149,633,000
Interest Exp TTM
$42,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,485,000
EBITDA
$-163,298,000
Free Cash Flow
$-90,184,376
Enterprise Value
$968,544,704
Total Cash
$422,833,984
Total Debt
$54,592,000
Shares Out
326,045,530
Trailing EPS
$-0.42
Book Value
$1.09
ROE
-54.2%
ROA
-27.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 9,773,000 -110,498,000 -108,995,000 343,320,000 96,382,000 246,938,000 -93,090,000
Dec 2024 8,333,000 -86,621,000 -89,298,000 160,364,000 88,839,000 71,525,000 -81,225,000
Dec 2023 15,451,000 -71,374,000 -111,566,000 172,731,000 97,794,000 74,937,000 -73,018,000
Dec 2022 2,502,000 -126,027,000 -166,014,000 126,276,000 125,327,000 949,000 -88,390,000

TTM Snapshot

Revenues TTM
$5,485,000
NetIncome TTM
$-149,633,000
OpCashFlow TTM
—
Assets (Latest)
$470,433,000
Forward EPS
$-0.39

Max Pain — expiry 2026-12-18

max pain strike: $2.50 · spot: $3.99 · call oi: 1,888 · put oi: 418
Expected Move to 2026-12-18: ±$1.10 (27.57%) — implied range $2.89 – $5.09 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVAX NOVAVAX INC $1.31B $7.96 —
IMCR Immunocore Holdings plc $1.43B $27.81 —
MEOBF MESOBLAST LTD $1.48B $1.14 —
VOR Vor Biopharma Inc. $1.12B $18.18 —
MESO MESOBLAST LTD $1.55B $11.91 —

News headlines (Yahoo Finance, 1h cache)

Taysha Gene Therapies, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Taysha (TSHA) Q3 2026 Earnings Call Transcript
2026-11-13 06:13 · Yahoo
Taysha Gene Therapies Q3 Earnings Call Highlights
2026-11-12 21:14 · Yahoo
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-12 12:30 · Yahoo
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 13:00 · Yahoo
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
2026-11-05 13:00 · Yahoo
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
2026-10-19 02:07 · Yahoo
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
2026-10-09 18:12 · Yahoo
Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
2026-10-09 07:15 · Yahoo
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
2026-08-12 05:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.